Lipid transfection reagents

The pH-sensitive 2-amino pyridinyl compounds, combined with cationic polymers, address inefficiencies in lipid-based transfection by optimizing pH-dependent binding and release, achieving enhanced nucleic acid delivery to cells.

WO2026241333A1PCT designated stage Publication Date: 2026-11-19KYFORA BIO LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027898
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing lipid-based transfection reagents face challenges in efficiently delivering nucleic acids into cells due to suboptimal pH sensitivity and membrane penetration, leading to inadequate transfection efficiency.

Method used

Development of pH-sensitive lipid transfection reagents, particularly 2-amino pyridinyl compounds with specific pKa ranges and hydrophobicity, forming complexes with cationic polymers like PEI to enhance cargo delivery by binding and releasing nucleic acids at varying pH levels within cells.

Benefits of technology

The pH-sensitive lipid transfection reagents demonstrate significantly improved transfection efficiency, enabling efficient delivery of nucleic acids to the cytosol, surpassing commercial reagents by multiple folds, and maintaining stability for extended storage periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
Patent Text Reader

Abstract

This disclosure provides compositions and method of transfecting cells using lipid cell transfection reagents. This disclosure is further directed to transfection complexes comprising the lipids described herein in non-covalent association with at least one nucleic acid as a cargo to be delivered to the interior of a cell. This disclosure further relates to methods for the cell transfection reagents for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture.
Need to check novelty before this filing date? Find Prior Art

Description

LIPID TRANSFECTION REAGENTSRelated Applications

[0001] This disclosure claims the benefit of priority of U.S. Provisional Application No.63 / 804,919, filed May 13, 2025, the contents of which are herein incorporated in their entirety.Field

[0002] This disclosure relates to the general field of cell transfection reagents. In particular, this disclosure relates to lipid transfection reagents and methods and compositions thereof for transfecting cells and use thereof for the intracellular delivery of cargo.Technical Background

[0003] The following includes information that may be useful in understanding the present invention. It is not an admission that any of the information, publications or documents specifically or implicitly referenced herein is prior art, or essential, to the presently described or claimed inventions. All publications, patents, related applications, and other written or electronic materials mentioned or identified herein are hereby incorporated herein by reference in their entirety. The information incorporated is as much a part of the application as filed as if all of the text and other content was repeated in the application, and should be treated as part of the text and content of the application as filed.

[0004] Cellular transfection is a means by which selective cargo molecules can be introduced into a cell for further cellular machinery to act on said cargo. Cationic lipids and polymers are especially effective for delivering anionic molecules (e.g., nucleic acids) into cells. In part, the effectiveness of cationic lipids and cationic polymers, and positively charged complexes formed with cationic lipids and nucleic acids, is thought to result from enhanced affinity for cell surfaces, many of which bear a net negative charge. The net positive charge of lipid or polymer aggregates comprising a cationic lipid or cationic polymer enables the aggregate to bind polyanions, such as nucleic acids. Lipid aggregates containing DNA and RNA are known to be effective agents for efficient transfection of target cells.Brief Summary

[0005] The inventions described and claimed herein have many attributes and embodiments including, but not limited to, those set forth or described or referenced in thisPATENT'Brief Summary. It is not intended to be all-inclusive and the inventions described and claimed herein are not limited to or by the features or embodiments identified in this introduction, which is included for purposes of illustration only and not restriction.

[0006] This disclosure provides a compound of Formulae (I), (II), (III), or (IV):wherein n and m are independently selected from an integer from 1 to 18,b is an integer selected from 0 to 3,d is an integer selected from 0 to 3,PATENT g is an integer selected from 0 to 5,h is an integer selected from 0 to 5,Ri and R2 are independently selected from a C8-C24 saturated or unsaturated alkyl,Rx, Ry, R3 , R4 , R5 and Re are independently selected from H, C1-6 unsubstituted alkyl, C1-6 substituted alkyl, aryl, heteroaryl, or C2-6 alkyl amide, or wherein R3 and R4 together form a C5-8 cyclic alkyl or heterocyclyl, or wherein R5 and Re together form a C5-8 cyclic alkyl or heterocyclyl;Rio and Rn are independently selected from H, C1-6 unsubstituted alkyl, C1-6 substituted alkyl, C2-6 alkyl amide, heteroaryl, aryl, or Rio and Rn together form a 5- to 8-membered heterocyclyl,J is selected from halogen, cyano, nitro, carboxy, guanidino, amidino, hydroxy, CF3, -NR7R8, C1-6 unsubstituted alkyl, C1-6 substituted alkyl, -OR9, and sulfate, wherein R7 and Rs are independently selected from C1-6 unsubstituted alkyl or C1-6 substituted alkyl or hydrogen, wherein R9 is selected from C1-6 unsubstituted alkyl or C1-6 substituted alkyl,or a stereoisomer or salt thereof.

[0007] In some aspects, the compound of Formula (I) has the structure of Formula (I-wherein e is an integer selected from 0 to 3.

[0008] In some aspects, the compound of Formula (I-a) has the structure of Formula (I-aa)PATENT

[0009] In some aspects, this disclosure relates to a compound, stereoisomer or salt thereof, which has a structure of Formula (V):some aspects, Ri and R2 are independently selected from a C8-C24 unsaturated alkyl. There can be from one to four double bonds in the unsaturated alkyl. Each of the double bonds in the unsaturated alkyl chain can independently be in the cis- or trans- configuration. In some aspects, the double bonds are all in the cis-configuration.

[0010] In some aspects, this disclosure relates to a compound, stereoisomer or salt thereof, which has a structure of formula (VI), formula (VII), or formula (VIII), or formula (IX), or formula (XII):PATENT

[0011] In some aspects, this disclosure relates to a compound, stereoisomer, or salt thereof, which has a structure of formula (X) or (XI):PATENTwherein Ri and R2 are independently selected from a C8-C24 saturated or unsaturated alkyl,R3 , R4 , R5 and Re are independently selected from H, C1-6 unsubstituted alkyl, C1-6 substituted alkyl, or C2-6 alkyl amide,or a salt thereof. In some aspects, R3 , R4 , Rs and Re can each be H.

[0012] In some aspects, this disclosure provides for an imidazolidine-based transfection lipid comprising the structure of formula (XIII):wherein Ri and R2 are as described herein.PATENT

[0013] In some aspects, this disclosure relates to a transfection composition comprising a compound of formula(I), (II), (III), or (IV), and a cationic polymer. The transfection composition can further comprise a nucleic acid. The nucleic acid can be DNA, shRNA (short hairpin RNA), siRNA (small interfering RNA), circRNA (circular RNA), circDNA, a CRISPR guide RNA, or mRNA (messenger RNA). In some aspects, the DNA can be plasmid DNA. The mRNA can comprise pseudouridine, a 5 -methylcytidine residue, a 5'-cap, a 5'-cap 1 structure, a 3'-poly(A) tail, or combinations thereof. In some aspects, the cationic polymer can be polyethyleneimine (PEI), ethoxylated polyethyleneimine, polypropyleneimine, poly(amidoamine), polyamine dendrimers from Go to G4 (PAMAM), polyhydroxyalkylamine, poly (butyleneimine), spermine, polyallylamine, N-substituted polyallylamine wherein the substitution on N is C1-6 alkyl or hydroxy, and combinations thereof. The polyethyleneimine can be linear polyethyleneimine or branched polyethyleneimine.

[0014] In some aspects, the transfection composition comprises a cationic polymer which is polyethyleneimine (PEI). The PEI can be linear PEI or branched PEI. The branched PEI can have the following structure:R = CH2CH2NR'R"R = Hwhere n is an integer from 10 to 100,000 and from 20 to 85 molar percent of the R groups are CfECfENR'R”, wherein R' and R" are is independently selected from H, OH, or an extended branch of CH2CH2NR'R" (representing branched PEI). When R' and R" are both H, the PEI is linear PEI.

[0015] In some aspects, this disclosure relates to a method for transfecting a cell, the method comprising contacting the cell with a transfection composition as described herein. In some aspects, the method comprises first forming a precomplex comprising a compound of formulae (I), (II), (III), or (IV), a cationic polymer, and a nucleic acid, prior to contacting the composition to a cell.PATENTBrief Description of Drawings

[0016] The drawings form part of the present specification and are included to further demonstrate certain aspects of the embodiments described herein. These embodiments may be better understood by reference to one or more of the following drawings in combination with the detailed description.

[0017] FIG. 1 shows the estimated pKa values of protons various substituted 2-amino pyridines, identifying the appropriate pKa for transfection capability.

[0018] FIG. 2 shows the estimated pKa values of protons on 2-amino pyridines compared to the pKa values of protons on analogous nitrogen-heteroaryl compounds, demonstrating that 2-amino pyridines are the better heteroaryl compounds for use as transfection reagents. 2-amino pyridinyl compounds exhibit pKa values within the desired range (highlighted in the middle) whereas certain nitrogen containing heterocycles (pyrimidines, piperazines, and morpholines) exhibit a pKa value outside of the range that can provide a change in charge beneficial to use as a transfection reagent.

[0019] FIG. 3 shows the transfection efficiency of various transfection reagents of this disclosure, compared to commercial reference transfection reagents (MaxGene, FectoVIR, and TransIT). 92A-E = ODAP Lipid w / 2-dimethylamino-pyridine ligand blended with EPEI at different (w / w) ratios: 92A= 1:4, 92B= 2:3, 92C= 1:1, 92D= 3:2, 92E= 4:1. 94A-E = ODAP Lipid w / 2-amino-pyridine ligand blended with EPEI (ethoxylated PEI) at different ratios: 94A= 1:4, 94B= 2:3, 94C= 1:1, 94D= 3:2, and 94E= 4:1. The results demonstrate that the transfection reagents of this disclosure exhibit significant multi-fold transfection improvement over control transfection reagents. (vg / mL = vector genomes per milliliter, a metric used to measure the amount of viral DNA or genome copies present in a specific volume of a sample).

[0020] FIG. 4 shows the relative transfection efficiency for formulations of lipids containing a 2-Aminopyridine ligand with an amino group on the pyridine ring and not part of the connecting linker which typically yielded vg titers that exceeded those obtained with a pendant imidazole (e.g. TransIT reagent).PATENT

[0021] FIG. 5 shows the average relative transfection efficiency results for formulations (A-E) of lipids containing a 2-Aminopyridine ligand with the linker chain attached via the amino group.Detailed Description

[0022] This disclosure relates to pH-sensitive lipid transfection reagents and methods of their use in cell transfection.

[0023] Without being bound by theory, it is understood that endocytosis involves a reduction in the pH value as an agent enters a cell. Transfection involves the assisted transport of a cargo into a cell, by which the cargo is exposed to a more acidic environment as the cargo enters the cell. pH-sensitive transfection reagents offer the ability to selectively assist transfection into a cell but then release the cargo after the cargo is endocytosed. The inventors have identified certain substituted heteroaryl compounds which are efficient cell transfection reagents. The primary property associated with the selected heteroaryl compound efficient transfection reagents exhibit (1) a pKa between 8.0 (extracellular pH) to 5.2 (endocytosed region) to selectively bind-release cargo into the cell, (2) appropriate hydrophobicity to penetrate the lipid bilayer membrane within the cell wall such that the transfection agent exhibits a fusagenic structure. The present disclosure describes certain 2-amino pyridinyl compounds, in particular, aliphatic substituted 2-amino pyridinyl compounds, which are transfection reagents in that they assist in the delivery of certain cargo into the cell.

[0024] When formed as a complex with a nucleic acid, the positively charged transfection compound of formula (I), (II), (III), or (IV) binds to the negatively charged nucleic acid by ionic interaction. At extracellular pH (typically around 7.2), the transfection compound is positively charged (that along with the charges on the cationic polymer components of the formulation, provides a nucleic acid-transfection reagent complex with a sufficient positive charge to be attracted to and taken into cells, which typically carry a negative charge). After internalization of the complex, the compounds of formula (I), (II), (III), or (IV), by nature of their pKa within a range of 5.5 to 8.0, will become more positively charged, thereby releasing the nucleic acid into the cytosol (through a combination of disrupting hydrogen bonding, the proton sponge effect, and the umbrella effect contributed by the accompanying cationic polymer components). The inventors have recognized this pKa-PATENT optimized transfection carrier property as especially advantageous for the enhanced transfection efficiency of the transfection reagents of this disclosure.

[0025] This disclosure provides compounds that may be used in combination with transfection reagents, e.g., PEI, the inclusion of which in a transfection complex further improve the transfection efficiency of cells in part by enhancing the transport of a cargo molecule, e.g., a nucleic acid molecule or any other suitable cargo molecule across the cell membrane such that the cargo molecule is delivered to the cytosolic compartment of a cell in culture or in a tissue in vivo.

[0026] The compounds of this disclosure can be complexed with a cargo before presentation to a target cell for transfection, or can be contacted to a target cell at different times (e.g., serially). When presented to a target cell as a pre-formed complex, the transfection reagent and the cargo molecule exhibit enhanced delivery of the cargo molecule to the cytosolic compartment of the cell or tissue.

[0027] In some embodiments, the transfection reagent compositions of this disclosure and at least one cargo molecule form a transfection complex comprising the transfection reagent, the cargo, and exhibit improved transfection efficiency (measured as improved transfer of the cargo to the interior of a cell in culture or in a tissue in vivo) of a complex compared to an identical transfection complex that lacks the transfection reagent of this disclosure.Certain Methods

[0028] In some embodiments, this disclosure provides for a transfection method which comprises the step of contacting a cell, preferably a eukaryotic cell, with a transfection complex comprising at one or more compounds of formula (I), (II), (III), or (IV). The complex optionally may also contain one or more additional transfection reagents, such as a cationic polymer (e.g., PEI).

[0029] In some embodiments, this disclosure provides for methods that enhance or to promote the transfer of a molecule, such as a cargo molecule, in particular a nucleic acid molecule such as a DNA or an RNA molecule, from an extracellular compartment, such as, e.g., a cell culture medium or an interstitial or body fluid, across a cell membrane such thatPATENT the cargo molecule is conveyed to the cytoplasmic compartment of the cell where it can effect at least one measurable biological response or function.

[0030] In some embodiments, this disclosure provides for a method of transfecting a cell using a composition comprising a compound of formula (I), (II), (III), or (IV). The transfection reagent can first form a complex with a cargo (e.g., nucleic acid) to form a transfection complex. The transfection complex, once formed, is stable in aqueous solution and can either be contacted with a cell or a tissue in a human or an animal immediately after being formed, or can be stored for a period prior to being contacted with the cell or tissue. The transfection complex is stable and can be stored for a time period of at least 30 minutes, at least 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 10 hours, at least 15 hours, at least 20 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 5 days, at least 7 days, at least 14 days, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months or at least 1 year, or any time period between the aforementioned time periods. It is understood, that the storage period can be between any of these time periods, for example between 31 minutes and 1 hour or between 1 hour and 24 hours.

[0031] In some embodiments, the transfection reagent compositions of this disclosure can further comprise one or a combination of a cationic polymer. In some aspects, the cationic polymer is polyethyleneimine (PEI). In some aspects, the PEI is linear. In some aspects, the PEI is branched. In some aspects, the cationic polymer is ethoxylated PEI (ePEI). In some aspects, ePEI can have the following formula:R = CH2CH2NR'R"R = Hwhere n is an integer from 10 to 100,000 and from 20 to 85 molar percent of the R groups are CfECfENR'R”, wherein R' and R" are is independently selected from H, OH, or an extended branch of CH2CH2NR'R" (representing branched PEI). When R' and R" are both H, the PEI is linear PEI.iiPATENT

[0032] In some embodiments, the molecular weight of PEI is from 12kDa to 50 kDa. In some embodiments, t he molecular weight of PEI is from 20 kDa to 30 kDa. The molecular weight is the mean average molecular weight as measured by GPC-MALLS using well-understood measurement methods.

[0033] In some embodiments, the transfection reagent compositions of this disclosure can further comprise agents that are known to further enhance polycationic polymer transfection, e.g. chloroquine or PLUS™ Reagent (Invitrogen Corporation).

[0034] In some embodiments, this disclosure provides for a method of transfecting a cell by contacting said cell with a compound of formula (I), (II), (III), or (IV) bound by non-covalent association to a nucleic acid or other cargo to be introduced into a cell to form a transfection complex. The transfection complexes are then admixed with an additional transfection agent (or mixture of agents) and the resulting mixture is employed to transfect cells. Preferred transfection agents are cationic polymers, further cationic lipid compositions, e.g., cationic lipid compositions composed of a 1:1 to 4:1 mixtures of a compound of formula(I), (II), (III), or (IV) and DOPE and a 1:1 to 4:1 mixtures of a compound of formula (I), (II), (III), or (IV) and cholesterol, as well as a 1:1 to 4:1 mixtures of a compound of formula (I),(II), (III), or (IV) and DOPC, more particularly a compound of formula (I), (II), (III), or (IV) compositions composed of a 1:1 to 4:1 mixtures of dihydroxyl-dimyristylspermine tetrahydrochloride and DOPE and a 1:1 to 4:1 mixtures of dihydroxyl-dimyristylspermine tetrahydrochloride and cholesterol, as well as a a 1:1 to 4:1 mixtures of dihydroxyl-dimyristylspermine tetrahydrochloride and DOPC as well as a 1 : 1 to 4: 1 mixtures of hydroxyl-dimyristylspermine tetrahydrochloride and DOPE and a 1:1 to 4:1 mixture of hydroxyl-dimyristylspermine tetrahydrochloride and cholesterol, as well as a 1:1 to 4:1 mixtures of hydroxyl-dimyristylspermine tetrahydrochloride and DOPC.

[0035] The step of contacting a cell with a compound of formula (I), (II), (III), or (IV) to effect transfection can be applied to cells in vitro, ex vivo, and in vivo, particularly for transfection of eukaryotic cells or tissues including animal cells, human cells, non-human animal cells, insect cells, plant cells, avian cells, fish cells, mammalian cells and the like. The cargo that is to be delivered into the cell is contacted with one or more of a compound of formula (I), (II), (III), or (IV) to form a complex. The target cell or cells are then incubated with the complex, or, for in vivo applications, the complex is administered to the organism so that the complex contacts the target cells or tissue. The compounds of formula (I), (II), (III),PATENT or (IV) may also be conjugated to or mixed with or used in conjunction with a variety of useful molecules and substances, also referred to as transfection helpers, such as proteins, peptides, growth factors and the like to enhance cell-targeting, uptake, internalization, nuclear targeting and expression.

[0036] In some embodiments, the cell is a target cell. The target cell can be an animal cell that is maintained in tissue culture such as cell lines that are immortalized or transformed. The target cell can include or exclude the following cell types: (American Type Culture Collection (Bethesda)): NIH3T3 (mouse fibroblast) cells, Rat 1 (rat fibroblast) cells, CHO (Chinese hamster ovary) cells, CV-1 (monkey kidney) cells, COS (monkey kidney) cells, 293 (humanembryonic kidney) cells, HeLa (human cervical carcinoma) cells, HepG2 (human hepatocytes) cells, Sf9 (insect ovarian epithelial) cells, Cos7, primary fibroblast, A549, Be2C, SW480, Caco2, primary neurons, Jurkat, C6, THP1, IMR90, HeLa, ChoKl, GT293, MCF7, HT1080, LnCap, HepG2, PC 12, SKBR3, and K562 cells.

[0037] In some embodiments, this disclosure provides for transfection reagent compositions and methods for in vitro and in vivo transfection of cells, particularly of eukaryotic cells, and more particularly to transfection of higher eukaryotic cells, including animal cells. The methods can be used to generate transfected cells which express useful gene products. The methods can also be employed as a step in the production of transgenic animals. The methods can be useful as a step in any therapeutic method requiring introduction of nucleic acids into cells including methods of gene therapy and viral inhibition and for introduction of antisense or antigene nucleic acids, ribozymes, RNA regulatory sequences, siRNA, RNAi, Stealth® RNAi (Invitrogen Corporation, Carlsbad Calif.) or related inhibitory or regulatory nucleic acids into cells.

[0038] Administration of the transfection reagent compositions of this disclosure be achieved orally, intravenously, or by subcutaneous or intramuscular injection or applied topically to the tissue or to cells in culture in a laboratory setting.

[0039] Exemplary diluents for complexation reactions, for example, include reduced-serum, or serum-free media, such as D-MEM and RPMI 1640 and OptiPro™, Opti-MEM® (Invitrogen Corporation). Incubation times for forming complexes can be determined using routine methods, although typical incubation times are between 5 and 240 minutes. In addition, it will be understood that media for culturing of cells before and after transfectionPATENT can be chosen based on the cell line to be transfected and based on the particular application of the method. For the production of proteins in suspension cells, reduced serum, or advantageously serum-free, medium can be used. In some embodiments, animal origin-free medium is employed which can include or exclude 293 Expression Medium (Invitrogen Corporation) and CD-CHO Medium (Invitrogen Corporation). In some embodiments, antibiotics can be excluded from post-transfection media. Incubation times for posttransfection culturing of cells can vary depending on the cell type and the desired outcome of the transfection, but can range from 2 hours to 7 days, or from 1 day to 7 days.

[0040] In some embodiments, the transfection reagent compositions described herein may optionally include one or more transfection helpers or targeting moieties. A targeting moiety may be a peptide, a modified peptide, an antibody, a modified antibody, a receptor molecule, a modified receptor molecule, a single or a double stranded nucleic acid molecule, a modified single or double stranded nucleic acid molecule, a peptide or nucleic acid aptamer, a modified peptide or nucleic acid aptamer, an organic molecule, a polysaccharide, or any other molecule that is capable of targeting a transfection complex to specific tissue or cell type for targeted delivery of a biologically agent thereto, such as will be readily apparent to have having ordinary skill level in the art. In some embodiments, modification of a peptide, an antibody, a nucleic acid, an aptamer, and the like may include conjugating the peptide, antibody, nucleic acid, aptamer, and the like to a PEG moiety. Alternatively, modification of a peptide, an antibody, a nucleic acid, an aptamer, and the like may include conjugating the peptide, antibody, nucleic acid, aptamer, and the like to a PEG-lipid moiety A variety of targeting moieties are widely known to those skilled in the art, and all are contemplated for use with the presently described embodiments, without limitation.

[0041] In some embodiments, the concentration of one or more compounds of formula (I), (II), (III), or (IV) in the composition can be between 1 mg / ml and 4 mg / ml, between 100 pg / ml and 10 mg / ml, between 1 mg / ml and 5 mg / ml, between 2 mg / ml and 4 mg / ml, or any concentration between the aforementioned values. In some embodiments, the concentration of the one or more compounds of formula (I), (II), (III), or (IV) in the composition can be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5,1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6,3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 mg / ml or any concentration between the aforementioned values. In some embodiments, the concentration of thePATENT combination of one or more compounds of formula (I), (II), (III), or (IV) and the cationic polymer in the composition can be between 1 mg / ml and 4 mg / ml, between 100 pg / ml and 10 mg / ml, between 1 mg / ml and 5 mg / ml, between 2 mg / ml and 4 mg / ml, or any concentration between the aforementioned values. In some embodiments, the concentration of the combination of one or more compounds of formula (I), (II), (III), or (IV) and the cationic polymer in the composition can be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2,1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3,3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 mg / ml or any concentration between the aforementioned values.

[0042] In some embodiments, this disclosure provides for a lipid nanoparticle comprising a lipid of formula (I), (II), (III), or (IV) and one or more lipids as discussed herein. The lipid nanoparticle may further comprise a nucleic acid. The nucleic acid can be a nucleic acid as discussed herein, and include DNA, RNA, siRNA, mRNA, shRNA, and the like.Methods of Screening

[0043] In some embodiments, this disclosure provides for methods for screening tissue-biased delivery of a transfection complex comprising the lipids of this disclosure by preparing a plurality of transfection complexes, where each transfection complex has at least one test transfection transfection copolymer and at least one nucleic acid that facilitates detection of delivery to a tissue. The nucleic acid may be an RNA molecule or a DNA molecule that encodes a protein that can be directly detected (e.g., Green Fluorescent Protein (GFP), red Fluorescent Protein, Luciferase, mNeonGreen), or encode a protein that effects expression of a protein that can be directly detected.Therapeutic Methods

[0044] In some embodiments, this disclosure provides for methods for preparing medicaments by combining lipids of this disclosure with a nucleic acid, wherein introduction of the nucleic acid into a cell or tissue modulates expression of one or more target genes therein thereby effecting at least one biological response and / or at least one therapeutic benefit. In some embodiments, the medicament can further comprise one or more additional lipids as described herein. Optionally the medicament further comprises an additional excipient or pharmaceutical carrier. In some embodiments, the nucleic acid is a DNA orPATENTRNA. In some embodiments, the nucleic acid is mRNA, RNAi, siRNA, shRNA, miRNA or stRNA, and is optionally chemically modified. In some embodiments, medicaments or pharmaceutical preparations are provided for treatment of a disease, condition, or disorder that relates to the expression of one or more genes in a cell or a tissue. Administration of the medicament delivers an effective amount of the polyanion, for example RNA or a DNA, to the cells or tissue associated with the disease, condition, or disorder to provide amelioration of the disease, condition or disorder. Such medicaments can be administered orally, intravenously, by inhalation, by insufflation, or by subcutaneous or intramuscular injection or applied topically to the tissue.Definitions

[0045] As used herein, the term “about” refers to the stated value and typical degrees of error of the measurement of said value. If not otherwise explicitly recited herein, the term “about” refers to any number within + / - 10% of the recited value.

[0046] The term “and / or” as used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example “A and / or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.

[0047] As used herein, the term “C10-C24 saturated or unsaturated alkyl refers to any monovalent radical of a linear or branched hydrocarbon chain comprising 10 to 24 carbon atoms. A “saturated C10-24 alkyl” refers to the aforementioned hydrocarbon chain that does not include any double or triple bonds. An “unsaturated C10-24 alkyl” refers to the aforementioned hydrocarbon chain that includes one to four double bonds, triple bonds, or combinations thereof. Typical alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl, docosyl, tetracosyl, hexacosyl, octacosyl and triacontyl groups.

[0048] As used herein, the term “alkenyl” refers to a radical comprising a carboncarbon unsaturated double bond. Useful alkenyl groups are straight chain or branched C2-30 alkenyl, preferably C4-75 alkenyl, more preferably Ce-64 alkenyl, more preferably Cs-so alkenyl, more preferably Cs-40 alkenyl, more preferably Cs-30 alkenyl, more preferably Ce-30 alkenyl, more preferably C4-30 alkenyl, most preferably Cs-24 alkenyl. Typical C2-30 alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec.-butenyl, hexenyl, octenyl, decenyl,PATENT dodecenyl, especially 9-dodecenyl, tetradecenyl, especially 9-tetradecenyl, hexadecenyl, especially 9-hexadecenyl, octadecenyl, especially 9-octadecenyl, eicosenyl, docosenyl, tetracosenyl, hexacosenyl, octacosenyl and triacontenyl.

[0049] As used herein, the term “alkynyl” refers to a radical comprising a carboncarbon unsaturated triple bond. Useful alkynyl groups are straight chain or branched C2-30 alkynyl, preferably C4-30 alkynyl, more preferably Ce-28 alkynyl, more preferably Cs-24 alkynyl. Typical C2-30 alkynyl groups include ethynyl, propynyl, butynyl, -butynyl, hexynyl, octynyl, decynyl, dodecynyl, tetradecynyl, hexadecynyl, octadecynyl, eicosynyl, docosynyl, tetracosynyl, hexacosynyl, octacosynyl and triacontynyl groups.

[0050] As used herein, the term “an amide group” refers to an organic radical having — NHC(O) — as a functional group. Typical amide groups include alkyl amides, alkenyl amides, alkynyl amides, and aryl amides, wherein alkyl, alkenyl, alkynyl and aryl are as defined above.

[0051] As used herein, the term “C1-6 unsubstituted alkyl” refers to any monovalent radical of a linear or branched hydrocarbon chain comprising 1 to 6 carbon atoms. The term “Ci-Ce alkyl” represents an alkyl group having 1 to 6 carbon atoms. Examples of suitable Ci-Ce alkyl groups include, but are not limited to, C1-C4 alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl.

[0052] As used herein, the term “C1-6 substituted alkyl” refers to alkyl group as defined herein substituted by one or more heteroatoms such as O, N, or S.

[0053] As used herein, the term “C2-6 alkyl amide” refers to represents an alkyl group as defined herein substituted with an amide moiety.

[0054] As used herein, the term “C5-8 cyclic alkyl” refers to any monovalent radical of a monocyclic or bicyclic 5 to 8 membered ring containing a cyclic alkyl ring. Examples include cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0055] As used herein, the term “heterocyclyl” refers to any monovalent radical of a monocyclic or bicyclic 5 to 8 membered ring containing one or more heteroatoms such as O, N, or S. Examples of suitable heterocyclyl groups include, but are not limited to, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl or azepanyl.PATENT

[0056] As used herein, the term “aryl” refers to an unsaturated C5-C18 ring or fused rings comprising an aromatic conjugation. Useful aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, fluorenyl, pyrenyl, aceanthrenyl, cholantrenyl, acephenanthrenyl, violantherenyl, hexaphenyl, hexacenyl, trinaphtyl and pyranthyl groups.

[0057] As used herein, the term “halogen” refers to an atom of F, Cl, Br or I.

[0058] Unless mentioned otherwise, the groups and radicals defined hereinabove may be unsubstituted or substituted by one or more substituents such as, for example, halogen, alkyl, alkoxy, aryl, heteroaryl, haloalkyl, haloalkoxy, alkoxycarbonyl, alkanoyl, aroyl, formyl, nitrile, nitro, amido, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl, arylsulfonyl, amino, alkylamino, arylamino, dialkylamino and diarylamino.

[0059] “Enhancing the transfection” refers to increasing the transfection yield relative to an indicated control, e.g., TransIT™ or MAXgene™ transfection reagents, of the same cargo in the two different transfection systems. In some embodiments, the transfection enhancement can be at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or greater for that of the transfection reagents of this disclosure relative to that of an indicated control.

[0060] As used herein, the term “cargo” refers to any substance that is to be conveyed to the interior of a cell, either in culture in a laboratory or in a tissue in an animal or a human. In some embodiments, a cargo includes a nucleic acid. In some embodiments, a cargo is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The DNA can be either linear DNA or circular DNA, such as DNA in the form of a circular plasmid, an episome or an expression vector. In some embodiments, the DNA includes at least one open reading frame operably linked to one or more nucleic acid sequence required for the transcription of an mRNA from the expressible nucleic acid sequence. In some embodiments, the RNA molecule may be any type of RNA molecule, including mRNA, a siRNA, a miRNA, shRNA, an antisense RNA, a ribozyme, or any other type or species of RNA molecule which would be suitable to be delivered to the interior of a cell.PATENT

[0061] As used herein the term “salt” for a cationic species, refers to a counterion such as chloride, bromide, fluoride, phosphate, citrate, acetate, nitrate, propionate, carbonate, succinate, sulfonate, tosylate, sulfate, or carboxylate. A “salt” for an anionic species refers to a counterion such as ammonium, tetramethylammonium, sodium, potassium, lithium, calcium, and magnesium.

[0062] As used herein, the term “transfection” refers to the delivery of nucleic acid, protein or other macromolecule to a target cell, such that the nucleic acid, protein or other macromolecule is expressed or has a biological function in the cell.

[0063] As used herein, the term “transfection reagent” refers to a compound or composition that facilitates the entry of a cargo into a cell. In some embodiments, the transfection reagent increases the uptake of one or more nucleic acids into one or more target cells. Transfection reagent compositions can comprise one or more compounds of Formula (I), (II), (III), or (IV) and a cationic polymer. In some embodiments, the cationic polymers can include or exclude: polyethyleneimine (PEI), ethoxylated polyethyleneimine (ePEI), polymers of positively charged amino acids such as polylysine and polyarginine, positively charged dendrimers (Go to G4 (PAMAM), polypropyleneimine, poly(amidoamine), polyhydroxyalkylamine, poly(butyleneimine), spermine, polyallylamine, N-substituted polyallylamine wherein the substitution on N is C1-6 alkyl or hydroxy, cationic P-cyclodextrin containing polymers (CD-polymers), and DEAE-dextran. The PEI can be linear PEI or branched PEI. In some embodiments, a transfection reagent composition includes one or more compounds of Formula (I), (II), (III), or (IV) and one or more lipids which can be cationic lipids and / or neutral lipids. Preferred lipids include, but are not limited to, N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylamonium chloride (DOTMA), dioleoylphosphatidylcholine (DOPE), l,2-Bis(oleoyloxy)-3-(4'-trimethylammonio) propane (DOTAP), l,2-dioleoyl-3-(4'-trimethylammonio) butanoyl- sn- glycerol (DOTB), 1,2-dioleoyl-3-succinyl-sn-glycerol choline ester (DOSC), cholesteryl (4'-trimethylammonio)butanoate (ChoTB), cetyltrimethylammonium bromide (CTAB), l,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide (DORI), l,2-dioleyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE), l,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE) , 0,0'-didodecyl-N - [p(2-trimethylammonioethyloxy)benzoyl] -N,N,N -trimethylammonium chloride, spermine conjugated to one or more lipids (for example, 5-carboxyspermylglycine dioctadecylamide (DOGS), N,NI,NII,NIII-tetramethyl-N,NI,NII,Nni-PATENT tet-rapalmitylspermine (TM-TPS) and dipalmitoylphasphatidylethanolamine 5-carboxyspermylaminde (DPPES)), lipopolylysine (polylysine conjugated to DOPE), TRIS (Tris(hydroxymethyl)aminomethane, tromethamine) conjugated fatty acids (TFAs) and / or peptides such as trilysyl-alanyl-TRIS mono-, di-, and tri-palmitate, (3 -[N — (N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), N-(a-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dimethyl dioctadecylammonium bromide (DDAB), 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-l-propanamin-iniumtrifluoroacetate (DOSPA) and combinations thereof.

[0064] Transfection reagent compositions of this disclosure include combinations of one or more compounds of Formula (I), (II), (III), or (IV) and other transfection reagents for the introduction of nucleic acids into cells at certain relative concentrations, for example a 3:1 (w / w) combination of DOSPA and DOPE is available from Life Technologies Corporation, Carlsbad, Calif, under the trade name LIPOFECTAMINE™, a 1:1 (w / w) combination of DOTMA and DOPE is available from Life Technologies Corporation, Carlsbad, Calif, under the trade name LIPOFECTIN®, a 1:1 (M / M) combination of DMRIE and cholesterol is available from Life Technologies Corporation, Carlsbad, Calif, under the trade name DMRIE-C reagent, a 1:1.5 (M / M) combination of TM-TPS and DOPE is available from Life Technologies Corporation, Carlsbad, Calif, under the trade name CELLFECTIN® and a 1:2.5 (w / w) combination of DDAB and DOPE is available from Life Technologies Corporation, Carlsbad, Calif, under the trade name LIPFECTACE®.

[0065] The term “cell” or “target cell” as used herein refers includes all types of eukaryotic and prokaryotic cells. In preferred embodiments, the term refers to eukaryotic cells, especially cells grown in culture, or cells found in a tissue in an animal, insect, or a human. In some embodiments, a cell refers to a mammalian cell. In certain exemplary though non-limiting embodiments, the term “cell” is meant to refer to any cell and cell line that is routinely used in research and clinical settings, and may include immortalized cell lines, transformed cell lines, or primary cells, without limitation.

[0066] By ‘ ‘cell culture” or “culture” is meant the maintenance of cells in an artificial, in vitro environment.

[0067] As used herein, the term “kit” refers to transfection, DNA, RNA, or other cargo (e.g., protein or anionic molecule) delivery or protein expression or knockdown kitsPATENT which include one or more of the compounds of this disclosure. The kits may further comprise PEI or other transfection reagents. In some embodiments, the kit may be provided in a single formulation. In other embodiments, the components of the kit may be provided separately, with instruction to the user to combine the reagents at the time of use. Such kits may comprise a carrying means being compartmentalized to receive in close confinement one or more container means such as vials, test tubes and the like. Each of such container means comprises components or a mixture of components needed to perform transfection.

[0068] The medium, methods, kit and composition of this disclosure can be used in either monolayer (e.g., adherent cells) or suspension culture, transfection, and cultivation of cells, and for expression of protein in cells in monolayer (e.g, adherent cells) or suspension culture.

[0069] The term “vector,” as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include plasmid, which are circular double stranded DNA into which additional DNA segments may be ligated, and phages, and a viral vector, wherein additional DNA segments may be ligated into the viral genome. Vectors can autonomously replicate in a target host cell into which they are introduced. Certain vectors, referred to herein as “expression vectors,” can also direct the expression of genes to which they are operatively linked. Vectors can be modified with one or more enhancers, one or more promoters, one or more ribosomal binding sites, one or more origins of replication, or the like. In some embodiments, expression vectors may further comprise one or more enhancer elements selected to improve expression of the protein of interest in the present transient expression system. The selected enhancer element may be positioned 5' or 3' to the expressible nucleic acid sequence used to express the protein of interest.

[0070] The terms “polynucleotide” and “nucleic acid” are used interchangeably herein and refer to any nucleic acid, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). In preferred embodiments, “nucleic acid” refers to DNA, including genomic DNA, complementary DNA (cDNA), and oligonucleotides, including oligo DNA. In certain preferred though non-limiting embodiments, “nucleic acid’ refers to genomic DNA and / or cDNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. In some embodiments, the RNA isPATENT mRNA, siRNA, or shRNA. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. In some embodiments, the modified nucleotides can be selected from pseudouridine, a 5-methylcytidine residue, a 5'-cap, a 5'-cap 1 structure, or a 3'-poly(A) tail. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may comprise modification(s) made after synthesis, such as conjugation to a label. Other types of modifications include, for example, “caps,” substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, phosphorothioates, and phosphorodithioates. Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, fluoro-, or phosphate groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl-, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs, and a-anomeric sugars. One or more phosphodiester linkages may be replaced by alternative linking groups which can be wherein phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), (0)NR2 (“amidate”), P(O)R, P(O)OR', CO, orCH2 (“formacetal”), in which each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether ( — O — ) linkage, aryl, or alkenyl.

[0071] As used herein the terms “complexation reaction,” refers to a reaction in which a nucleic acid is complexed to a transfection reagent formulation. Typically, a nucleic acid that is to be introduced into a cell for the purpose of expressing a protein is first complexed with a positively charged transfection reagent of this disclosure.

[0072] As used herein, the terms “subject”, or “patient” may mean either a human or non-human animal. The term includes, but is not limited to, mammals (e.g., humans, other primates, pigs, rodents (e.g., mice and rats or hamsters), rabbits, guinea pigs, cows, horses, cats, dogs, sheep, and goats). In certain embodiments, the subject is a human.

[0073] As used herein, “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired result. For example, and not by way of limitation, an “effective amount” can refer to an amount of a compound or composition, disclosed herein, that is able to effect the transfection and expression of a nucleic acid cargo into a cell.PATENT

[0074] A “carrier,” as used herein, refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which can be safely administered to a cell. A carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.Compositions

[0075] The present invention provides compounds and compositions for the transfection of cells. This disclosure provides compounds and compositions that enhance the transfection efficiency of all cells. The compounds and compositions of this disclosure, can typically increase the transfection efficiency of such cells by up to 10%, up to 15%, 20%, up to 25%, up to 30%, up to 35%, up to 40%, up to 45%, up to 50%, up to 55%, up to 60%, up to 65%, up to 70%, up to 75%, up to 80%, up to 85%, up to 90%, up to 95%, up to 100% or in excess of 100%. The methods of this disclosure accomplish this by providing a composition comprising one or more compounds of formula (I), (II), (III), or (IV) in combination with one or more cargo molecules, in particular but not limited to a nucleic acid molecule such as a DNA molecule or an RNA molecule, to the interior or cytoplasmic compartment of a cell in culture or a cell or tissue in vivo.

[0076] In some embodiments, the transfection reagent compositions of this disclosure can comprise a carrier vehicle. The carrier vehicle can further include or exclude: viscosity modifiers, stabilizers, preservatives, tonicity agents, solubilizers, and surfactants. While the concentration of a compound of formula (I), (II), (III), or (IV) can be from 0.1 to 50 wt.% of the total composition, the range of the other components may vary, and if selected, can be at any range up to the total composition weight.

[0077] The compound of formula (I), (II), (III), or (IV) may be present in the composition in a substantially isolated form. It will be understood that the product may be mixed with carriers or diluents that will not interfere with the intended purpose of the product and still be regarded as substantially isolated. A composition may also be in a substantially purified form, in which case it will generally comprise about 80%, 85%, or 90%, e.g. at least about 88%, at least about 90, 95 or 98%, or at least about 99% of a compound, or dry mass of the preparation.

[0078] Suitable carriers and diluents include aqueous and / or non-aqueous components which can include or exclude: water, DMSO, dextrose, glycerol, propylene glycol, Cl -Cl 8 monofunctional alcohols, Ci-Cis symmetrical alcohols, dimethyl isosorbide, andPATENT combinations thereof. In some embodiments the pharmaceutically acceptable carrier or diluent may be a buffer.

[0079] In some embodiments, the surfactant is a lipid. Preferred lipids include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

[0080] In some embodiments, the formulations of the inventions include a tonicity agent. The tonicity agent is present in an amount to achieve a final formulation tonicity between 220-360 mOsm / kG, preferably 250-340 mOsm / kG, and most preferably between 260 and 320. The tonicity agent can be ionic or non-ionic. Non-ionic tonicity agents include compounds comprising 1,2-diols, such as glycerol, mannitol, erythritol; and sugars such as dextrose. Other non-ionic tonicity agents which also function as cosolvents can also be used such as polyethylene glycol and propylene glycol. The non-ionic tonicity agent can be present in an amount of 0-20 %, preferably 0-10%, more preferably 0-5%. The non-ionic agents can be selected from: glycerol, mannitol and dextrose, in an amount 2-6%.

[0081] In some embodiments, the compositions can comprise a preservative. Suitable preservatives include benzyl alcohol, methyl parabens, propyl parabens, borate, chlorobutanol, and benzethonium chlorides. Typically, such preservatives are employed at a level of from 0.001-1%, preferably, 0.001-0.25%, and most preferably 0.001-0.2%.

[0082] Transfection reagent compositions of this disclosure can be provided in a variety of pharmaceutical compositions and dosage forms for therapeutic applications. In some embodiments, transfection reagent compositions can be in the form of injectable formulations, intranasal formulations and formulations for intravenous and / or intralesional administration containing these complexes can be used therapy.

[0083] The concentration of the compounds of one or more of formula (I), (II), (III), or (IV) in the pharmaceutical compositions of this disclosure should contain sufficient amount of the compound(s) and any enhancing agents to provide for introduction of a sufficiently high enough level of nucleic acid into the target cell or target tissue such that the nucleic acid has the desired therapeutic effect therein. The level of nucleic acid in the target cell or tissue that will be therapeutically effective will depend on the efficiency of inhibition or other biological function and on the number of sites the nucleic acid must affect.

[0084] The dosage of transfection reagent compositions described herein administered to a patient will depend on a number of other factors including the method and site ofPATENT administration, patient age, weight and condition. Those of ordinary skill in the art can readily adjust dosages for a given type of administration, a given patient and for a given therapeutic application.

[0085] The transfection reagent compositions of this disclosure are configured to contain minimal or none amounts of inhibitory components, such as serum or high salt levels, which may inhibit introduction of a cargo (e.g., nucleic acid) into the target cell, or otherwise interfere with transfection or nucleic acid complexation.Manufacture and Stability

[0086] In one aspect, the compositions of this invention will comprise an aqueous carrier. In one embodiment, the aqueous (e.g., hydrophobic) media and comprises one or more of buffers, salts, sugars.

[0087] In some embodiments, the formulations of this invention are substantially pure. By substantially pure is meant that the formulations comprise less than about 10%, 5%, or 1%, and preferably less than about 0.1%, of any compound impurity. In some embodiments the total impurities, will be not more than 15%. In some embodiments the total impurities, will be not more than 12%. In some embodiments the total impurities, will be not more than 11%. In other embodiments the total impurities, will be not more than 10%.

[0088] In some embodiments, the purity of the compounds of this invention may be measured using a method selected from anion exchange HPLC (AEX-HPLC) or mass spectrometry. Mass spectrometry may include LC / MS, or LC / MS / MS. The assay may in some embodiments comprise both AEX-HPLC and LC / MS.

[0089] Sterile compositions comprising the compounds of this invention prepared using aseptic processing by dissolving the compounds in the formulation vehicle. In one embodiment, the formulation may also be sterilized by filtration. Excipients used in the manufacture of the formulations of this invention are widely used in pharmaceutical products and released to pharmacopeial standards.Examples

[0090] General Experimental

[0091] All cells were maintained in an appropriate media supplemented with 10% fetal bovine serum. All cultures were maintained in a humidified atmosphere containing 5%PATENTC02 at 37 C. Approximately 24 hours prior to transfection, cells were seeded at an appropriate density to 24- well tissue culture plates and incubated overnight. Cells were generally 85% confluent at time of transfection.

[0092] The transfection complexes, which are generally ternary complexes, are prepared by mixing the plasmid DNA (pDNA) with an effective amount of an amphipathic compound and an effective amount of a polycation. In some cases the, the pDNA is mixed first with serum-free media or other non-toxic solution and then the polycation and amphipathic compound are added sequentially to the mixture. The mixture containing the ternary complex of pDNA, polycation and amphipathic compound is incubated at room temperature for 15-30 minutes then added to the cells. In other cases, the polycation and amphipathic compound are first mixed together prior to adding to the pDNA / serum free media mixture. The mixture containing the ternary complex of pDNA, polycation and amphipathic compound is incubated at room temperature for 15-30 minutes and then added to the cells.Example 1. Synthesis of Representative Transfection Reagents

[0093] Representative transfection reagents of this disclosure were made by the following reaction scheme:PATENTChemical Formula: C64H112N8O2Exact Mass: 1024.89

[0094] For the synthesis shown, Compound 1 was purchased from a commercial source (e.g,. Sigma-Aldrich, CAS: 1529563-28-7), and Compound 2 (also referred to herein as “ODAP”) was made using the methods described below. In some embodiments, the intermediate compounds can be made by methods previously reported (e.g. US8921448, herein incorporated by reference). The coupling was done using standard peptide coupling reagents (e.g. DMTMM, (4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methyl-morpholinium chloride)) and standard conditions (e.g. in CH2Q2 or chloroform at rt) and the material was purified by column chromatography on silica gel.

[0095] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))dioleamide. To a stirred solution of l-4-bis(3-aminopropyl)piperazine (1 g, 5 mmol) in 13 mL dichloromethane was added N,N-diisopropylethylamine (DIPEA, 0.91 mL, 5.24 mmol, 1.05 equiv) at room temperature. Oleoyl chloride (30 g, 10 mmol, 2 equiv) was dissolved separately in 13 mL DCM and added drop wise. The reaction mixture was stirred at rt for 16 hrs, then was washed twice with saturated aqueous sodium carbonate and the organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford aPATENT crude brown solid. The crude product was recrystallized in a mixture of acetonitrile and dichloromethane and then recrystallized a second time in acetonitrile. The crystalline product was dried in a vacuum oven at rt to afford N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))dioleamide as a white to off-white solid (2.62 g, 75%). MS (ESI) m / z (M+). 729.9

[0096] (9Z,9'Z)-N,N'-(piperazine- 1 ,4-diylbis(propane-3, 1 -diyl))bis(octadec-9-en- 1 -amine) (Compound 2). In a dried flask under nitrogen, lithium aluminum hydride (0.47 g, 12.3 mmol, 3.0 equiv) was suspended in 30 mL anhydrous THF. N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))dioleamide (3 g, 4.1 mmol) was dissolved in 30 mL THF and added dropwise to the LAH suspension. The reaction mixture was brought to reflux and stirred overnight (16-18 h) under nitrogen. The reaction mixture was cooled to 0 °C in an ice bath and quenched using NaOH and water with stirring to form a white gelatinous precipitate that was filtered under vacuum and washed with 30 mL THF. The combined filtrate was concentrated under reduced pressure to yield a crude yellow oil, which was redissolved in 30 mL methanol. The solution was cooled in an ice bath (0-5 °C), HC1 in isopropanol was added, and the resulting white precipitate was collected by vacuum filtration, washed with cold methanol and dried overnight in a vacuum oven at ambient temperature to afford the amine as its hydrochloride salt (2.65 g, 83.4% yield). MS (ESI) m / z (M+). 701.9

[0097] Compound 2 (1.0 equiv), was dissolved in chloroform and treated with N,N-diisopropylethylamine (DIPEA, 2.0 equiv). The dimethylaminopyridine-carboxylic acid potassium salt (1.1 equiv) was added, and the mixture was stirred until fully dissolved. 4-(4,6-Dimethoxy-l,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM, 1.2 equiv) was then added, and the reaction was stirred at room temperature for 4 h. Reaction progress was monitored by mass spectrometry and TLC (9:1 dichloromethane : 10% NH4OH in methanol). Upon completion, the reaction mixture was washed with water (2 x 20 volumes). The combined aqueous layers were back-extracted with dichloromethane (2 x 20 volumes). The organic layer was dried over anhydrous Na2SC>4, filtered, and concentrated under reduced pressure at 45 °C to afford a crude oil. The crude product was purified by column chromatography using 95:5 dichloromethane: 10% NH4OH in methanol to afford the desired product as an oil (400 mg, 56.3%).PATENT

[0098] Characterization Data (Compound 92): MS (ESI) m / z 1025.9 (M+H+), 1H NMR (CDCh, 500 MHz): 67.98 (d, 2H, 6.5 Hz), 67.42 (d, 2H, 9.5 Hz), 66.49 (d, 2H, 10.5 Hz), 65.34 (m, 4H, 10.5 Hz), 63.59 (d, 2H, 5.5Hz), 63.50 (s, 2H), 63.31-3.21 (m, 8H, 22 Hz), 63.05 (s, 12H), 62.29-2.04 (m, 12H), 62.02 (m, 8H, 20 Hz), 6 1.69-1.66 (m, 4H, 14 Hz), 6 1.49 (m, 4H), 6 1.30-1.26 (m, 44H), 60.88-0.85 (t, 6H, 14 Hz).

[0099] Compound 94 & 173:1H NMR (500 MHz, CDCh) 67.90-7.85 (d or br, 2H), 7.45-7.35 (m, 2H), 6.55-6.45 (d, 2H), 5.40-5.28 (m, 4H), 4.50-4.37 (m, 4H), 3.61-3.58 (s, 2H), 3.53-3.47 (s, 2H), 3.37-3.18 (m, 8H), 2.70-2.20 (br, 12H), 2.05-1.95 (t or br, 8H), 1.75-1.61 (br, 4H), 1.57-1.42 (br, 4H), 1.40-1.18 (m or br, 44H), 0.91-0.85 (t, 6H).

[0100] Compound 96: 'H NMR (500 MHz, CDCh) 67.95-7.85 (d or br, 2H), 7.40-7.30 (m, 2H), 6.53-6.40 (d, 2H), 5.40-5.28 (m, 4H), 4.65-4.30 (m, 4H), 3.61-3.58 (s, 2H), 3.53-3.47 (s, 2H), 3.37-3.15 (m, 8H), 2.83-2.78 (s, 4H), 2.70-2.20 (br, 12H), 2.05-1.95 (t or br, 8H), 1.75-1.58 (br, 4H), 1.57-1.42 (br, 4H), 1.40-1.18 (m or br, 44H), 0.91-0.85 (t, 6H).

[0101] Compound 128:1H NMR (500 MHz, CDCh) 67.95-7.85 (d or br, 2H), 7.45- 7.35 (m, 2H), 6.55-6.45 (d, 2H), 5.40-5.28 (m, 8H), 4.50-4.37 (m, 4H), 3.61-3.58 (s, 2H), 3.53-3.47 (s, 2H), 3.40-3.18 (m, 8H), 2.80-2.20 (br, 12H), 2.10-1.95 (t or br, 8H), 1.94-1.80 (br, 2H), 1.75-1.61 (br, 2H), 1.57-1.42 (br, 4H), 1.40-1.18 (m or br, 40H), 0.91-0.85 (t, 6H).PATENTExample 2. Synthesis of representative 2- Aminopyridine Lipids comprising an amine in linker to heteroaryl grouppKa(py) = 5.49PATENTCmpd. 98pKa(py) = 5.40

[0102] 2-Aminopyridine Lipids with Calculated pKa of the Pyridine Moiety (Calculation performed by software from ChemAxon Chemicalize).PATENT

[0103] General Procedure 1: Peptide Coupling of Boc-Protected Amino Acids to ODAP with PyBOP. (Reference: Experiment 00965-064). To a stirring solution of Compound 2 (ODAP or ODAP • 2 HC1; 1.00 equivalent) in CHC13 (0.1 M with respect to ODAP • 2 HC1) was added N,N-diisopropylethylamine (4.5 equiv). Solid PyBOP (2.20 equiv) was then added in a single portion, followed by the Boc-protected amino acid (2.20 equiv). Stirring continued at room temperature for 16 h, upon which time the reaction mixture was diluted with CHC13. The solution was washed with 10% aqueous citric acid solution, followed by DI water, and then saturated aqueous sodium bicarbonate solution. The CHC13 phase was dried using Na2SO4. The drying agent was filtered off and the filtrate liquid was concentrated under reduced pressure. Flash column chromatography on silica gel afforded the desired Boc-amino acid amides.

[0104] di-tert-butyl (((piperazine- l,4-diylbis(propane-3,l-diyl))bis(((Z)-octadec-9-en- l-yl)azanediyl))bis(2-oxoethane-2,l-diyl))bis(methylcarbamate) (2a). Prepared using general procedure A with 4.00 g ODAP • 2 HC1 (5.17 mmol) and a column gradient of 0-5% CH3OH / CH2C12. The product was obtained as a yellow-orange oil (3.30 g, 61% yield). 1H NMR (500 MHz, DMSO-d6): 65.30 (4 H); 3.96 (4H); 3.19 (12 H); 2.78 (6H), 2.43-2.25 (8 H), 1.95 (8H), 1.63 (4 H), 1.50-1.08 (66 H), 0.83 (6 H). Product was a single spot by TLC (5% CH3OH / CH2C12, 12 stain as indicator). TLC-MS (ES+) calc’d for C62H118N6O6 1042.91; found 1043.8 [M+H]+.PATENT

[0105] di-tert-butyl (((piperazine- l,4-diylbis(propane-3,l-diyl))bis(((Z)-octadec-9-en- l-yl)azanediyl))bis(2-oxoethane-2,l-diyl))dicarbamate (2b). Prepared using general procedure A with 1.68 g ODAP • 2 HC1 (2.17 mmol) and a column gradient of 0-8% CH3OH / CH2C12. The product was obtained as a yellow orange oil (991 mg, 45% yield) 1H NMR (500 MHz, DMSO-d6): 65.31 (4H); 3.74 (4H); 3.44-3.10 (8H), 2.87-3.04 (12 H), 2.28 (4H), 2.0 (8H), 1.03-1.42 (68 H), 0.83 (6H). Product was a single spot by TLC (8% CH3OH / CH2C12, 12 stain as indicator) TLC-MS (ES+) calc’d for C60H114N6O6 1014.88; found 1015.8 [M+H]+.2c

[0106] di-tert-butyl (((piperazine- l,4-diylbis(propane-3,l-diyl))bis(((Z)-octadec-9-en- l-yl)azanediyl))bis(3-oxopropane-3,l-diyl))bis(methylcarbamate) (2c). Prepared using general procedure A with 2.00 g ODAP (the freebase was used, 2.85 mmol) and a column gradient of 0-7% CH3OH / CH2C12. The product was obtained as yellow oil (1.75 g, 57% yield). 1H NMR (500 MHz, DMSO-d6): 65.31 (4H); 3.24-3.16 (14H), 2.81-2.64 (12H), 2.42 - 2.11 (13H)1.96 (8H), 1.01-1.43 (65H), 0.83 (6 H). LC / MS: 98.6% purity, ES+ calc’d for C64H122N6O6 1070.94; found 1072.0 [M+H]+.PATENT

[0107] 2ddi- tert-butyl (((piperazine- 1 ,4-diylbis(propane-3, 1 -diyl))bis(((Z)-octadec-9-en- 1 -yl)azanediyl))bis(3-oxopropane-3,l-diyl))dicarbamate (2d). Prepared using general procedure A with 424 mg ODAP • 2 HC1 (0.55 mmol) and a column gradient of 0-8% CH3OH / CH2C12. The product was obtained as yellow oil (437 mg, 76% yield). 1H NMR (500 MHz, DMSO-d6): 65.30 (4H); 3.29-3.06 (12 H), 2.42-2.03 (16 H), 1.92-1.77 (4 H), 1.64-1.52 (4 H), 1.49-1.36 (72 H), 0.83 (6 H). Product was a single spot by TLC (8% CH3OH / CH2C12, 12 stain as indicator) ES+ calc’d for C62H118N6O6 1042.91; found 1043.9 [M+H]+.

[0108] di-tert-butyl (((piperazine- 1, 4-diylbis(propane-3, 1 -diyl))bis(((Z)-octadec-9-en- l-yl)azanediyl))bis(4-oxobutane-4,l-diyl))dicarbamate (2e). Prepared using general procedure A with 2.00 g ODAP (the freebase was used, 2.85 mmol) and a column gradient of 0-5% CH3OH / CH2C12. The product was obtained as a yellow oil (1.80 g, 59% yield). 1H NMR (500 MHz, DMSO-d6): 65.30 (4H); 3.18 (8 H), 2.93-2.86 (4H), 2.44-2.12 (16 H), 1.95 (8H), 1.64-1.50 (8H), 1.48-1.14 (68H), 0.83 (6H). LC / MS: 95.8% purity, ES+ calc’d for C64H122N6O6 1070.94; found 1072.2 [M+H]+PATENT

[0109]

[0110] di-tert-butyl (((piperazine- l,4-diylbis(propane-3,l-diyl))bis(((Z)-octadec-9-en- l-yl)azanediyl))bis(5-oxopentane-5,l-diyl))dicarbamate (2f). Prepared using general procedure A with 424 mg ODAP • 2 HC1 (0.55 mmol) and a column gradient of 0-8% CH3OH / CH2C12. The product was obtained as a colorless oil (463 mg, 77% yield). 1H NMR (500 MHz, DMSO-d6): 65.29 (4H); 3.28 (8 H), 2.87 (4H), 2.43-2.02 (8 H), 1.96 (8H), 1.66-1.52 (4H), 1.51-1.39 (8H), 1.40-0.92 (76H), 0.83 (6H). The product was a single spot by TLC (12 stain as indicator). TLC-MS calc’d for C66H126N6O6 1098.97; found 1099.77 [M+H]+.

[0111]

[0112] General Procedure 2: Boc-Deprotection of ODAP Derivatives. (Reference: Experiment 00965-075). The Boc-protected ODAP derivative (2a-2f, 1.00 equiv) was dissolved in a 4.0 M solution of HCI in dioxane (Oakwood Chemical, Item# 094030, 15 equiv HCI). The flask was closed with a rubber septum and connected to a mineral oil bubbler via a needle and septum. The reaction mixtures were magnetically stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue was then further dried under high vacuum to constant mass to afford the desired products 3a-3f. ThePATENT dried solid was analyzed by TLC (using the same conditions as reported for the starting material) and ESI-MS to confirm a complete reaction had occurred. It was carried forward directly to the next step as a hydrochloride salt without further purification. The chemical yield of all products was assumed to be near-quantitative for this step.

[0113]

[0114] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-(methylamino)-N-((Z)- octadec-9-en-l-yl)acetamide) tetrahydrochloride (3a). Prepared from compound 2a (3.30 g, 3.16 mmol). Crude 3a was obtained as a yellow solid (3.18 g). ESI-MS: ES+ calc’d for C52H102N6O2 842.81; found 843.9 [M+H]+.

[0115]

[0116] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-amino-N-((Z)-octadec-9-en-l-yl)acetamide) tetrahydrochloride (3b). Prepared from compound 2b (991 mg, 0.91 mmol). Crude 3b was obtained as a green solid (898 mg). ESI-MS: ES+ calc’d for C50H98N6O2 814.78; found 816.0 [M+H]+.PATENT

[0117]

[0118] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(3-(methylamino)-N-((Z)- octadec-9-en-l-yl)propanamide) tetrahydrochloride (3c). Prepared from compound 2c (1.75 g). Crude 3c was obtained as a yellow solid (1.43 g). ESI-MS: ES+ calc’d for C54H106N6O2 870.84; found 871.9 [M+H]+.

[0119] HCI HCI3d

[0120] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(3-amino-N-((Z)-octadec-9-en-l-yl)propanamide) tetrahydrochloride (3d). Prepared from compound 2d (437 mg). Crude 3d was obtained as a colorless solid (381 mg). ESI-MS: ES+ calc’d for C52H102N6O2 842.81; found 843.9 [M+H]+.

[0121] 3ePATENT

[0122] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(4-amino-N-((Z)-octadec-9-en-l-yl)butanamide) tetrahydrochloride (3e). Prepared from compound 2e (1.80 g). Crude 3e was obtained as a light pink solid (1.38 g). ESI-MS: ES+ calc’d for C54H106N6O2 870.84; found 870.2 [M+H]+.

[0123]

[0124] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(5-amino-N-((Z)-octadec-9-en-l-yl)pentanamide) tetrahydrochloride (3f). Prepared from compound 2f (252 mg). Crude 3f was obtained as a colorless solid (212 mg). ESI-MS: ES+ calc’d for C56H110N6O2 898.87; found 899.9 [M+H]+.PATENT

[0125] (R = -H or-CH3)3a-3fCs2CO3(10 equiv)Cs2CO3(10 equiv)neat, 110 °C (Conditions A)DMSO, 80 °C (Conditions B)

[0126] General Procedure 3: Nucleophilic Aromatic Substitution with 2-Fluoropyridines. Conditions A: A round bottom flask equipped with a magnetic stir bar was charged with the crude hydrochloride starting material (3, 1.0 equivalent), 2-fluoropyridine (450 equivalents, neat), and cesium carbonate (10 equivalents). The flask was sealed with a rubber septum and connected to a dry N2 gas line equipped with a mineral oil bubbler. Then it was heated to 110 °C using an oil bath and the reaction was continued at that temperature for the specified time under an N2 atmosphere. Once the reaction was complete by TLC, excess 2-fluoropyridine was removed by distillation (50 °C at 2 mmHg), the residue was treated with CH2Q2 (100 mL), and silica gel (12 g) was added. CH2CI2 was then removedPATENT under reduced pressure, and the resulting solid phase was dry loaded onto a normal phase silica gel column. Flash column chromatography furnished the desired 2-aminopyridine product 4. Conditions B: To a 20 mL scintillation vial containing a magnetic stir bar and the hydrochloride starting material (3, 1.0 equivalent) was added cesium carbonate (10 equivalents), the appropriate 2-fluoropyridine reactant (50 equiv), and DMSO (2 M with respect to the 2-fluoropyridine compound). The vial was sealed with a PTFE septum and connected to a dry N2 gas line equipped with a mineral oil bubbler using a needle and tubing. The vial was heated at 80 °C under an N2 atmosphere until the reaction was complete by TLC. The vial was cooled to room temperature and the contents were partitioned between EtOAc (150 mL) and DI water (100 mL). The organic layer was then treated with Na2SO4, filtered, and concentrated under vacuum to a thick oil. The oils were chromatographed on normal phase silica gel to afford the desired 2-aminopyridine products 4.

[0127]

[0128] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-(methyl(pyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)acetamide) (4a): Prepared from compound 3a (500 mg, 0.51 mmol) using Conditions A with a flash column gradient of 0-12% CH3OH / CH2C12. 4a was obtained as a yellow oil (260 mg, 52% yield). 1H NMR (500 MHz, DMSO-d6): 67.97 (2H); 7.44 (2H); 6.56-6.48 (4H); 5.30 (4H); 4.39 (4H); 3.27 (4H); 3.17 (4H); 2.96 (6H); 2.86- 2.32 (9H); 1.95 (8H); 1.71 (2H); 1.55 (4H); 1.38 (2H); 1.34-1.12 (47H); 0.83 (6H). LC / MS: 93.8% purity, ES+ calc’d for C62H108N8O2996.86; found 997.9 [M+H]+.PATENT

[0129] 4b

[0130] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(3-((6-chloropyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)propanamide) (4b): Prepared from compound 3d (200 mg, 0.20 mmol) and 2-chloro-6-fluoropyridine (1.33 g, 10.1 mmol) using Conditions B with a flash column gradient of 0-5% CH3OH / CH2C12. 4b was obtained as a green oil (172 mg, 80% yield). 1H NMR (500 MHz, DMSO-d6): 67.32 (2H); 6.94 (2H); 6.44 (2H); 6.38 (2H);5.30 (4H); 3.39 (4H); 3.20 (8H); 2.53 (4H); 2.40-2.04 (9H); 1.95 (8H); 1.56 (4H); 1.41 (4H); 1.31-1.11 (44H); 0.83 (6H). LC / MS: 99.2% purity, ES+ calc’d for C62H106C12N8O2 1064.78; found 1065.8 [M+H]+.

[0131]

[0132] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-((6-chloropyridin-2-yl)(methyl)amino)-N-((Z)-octadec-9-en-l-yl)acetamide) (4c). Prepared from compound 3a (259 mg, 0.26 mmol) and 2-chloro-6-fluoropyridine (1.72 g, 13.1 mmol) using Conditions B with a flash column gradient of 0-5% CH3OH / CH2C12. 4c was obtained as a green oil (153 mg, 55% yield). 1H NMR (500 MHz, DMSO-d6): 67.43 (2H); 6.55 (4H); 5.30 (4H); 4.37 (4H); 3.49 - 3.13 (13H); 3.18-2.56 (11H); 2.83-2.20 (6H); 1.92 (8H); 1.78-1.69 (3H); 1.61PATENT(4H); 1.40 (3H); 1.37-1.08 (28H); 0.83 (6H). LC / MS: 97.9% purity, ES+ calc’d for C62H106C12N8O2 1064.78; found 1066.0 [M+H]+.

[0133]

[0134] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(3-(methyl(pyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)propanamide) (4d). Prepared from compound 3c (374 mg, 0.37 mmol) using Conditions A with a flash column gradient of 0-8% CH3OH / CH2C12.4d was obtained as a green oil (231 mg, 61% yield). 1H NMR (500 MHz, CDC13): 68.13 (2H); 7.43 (2H); 6.57-6.50 (4H); 5.34 (4H); 3.84 (4H); 3.35-3.25 (6H); 3.23 (3H); 3.05 (6H); 2.62 (5H); 2.54-2.09 (10H); 2.01 (9H); 1.53 (5H); 1.47 (5H); 1.40-1.07 (49H); 0.88 (6H). LC / MS: 95.9% purity, ES+ calc’d for C64H112N8O2 1024.89; found 1026.0 [M+H]+.

[0135] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)-3-(pyridin-2-ylamino)propanamide) (4e). Prepared from compound 3d (180 mg, 0.18 mmol) using Conditions A with a flash column gradient of 0-12% CH3OH / CH2C12. 4e was obtained as an orange oil (77 mg, 42% yield). 1H NMR (500 MHz, DMSO-d6): 6 7.93 (2H); 7.28 (2H); 6.41 (6H); 5.28 (4H); 3.41 (5H); 3.20 (10H); 2.51 (4H); 2.41-2.03 (10H); 1.96 (9H); 1.57 (4H); 1.40 (5H); 1.34-1.01 (51H); 0.83 (6H). LC / MS: 96.4% purity, ES+ calc’d for C62H108N8O2996.86; found 998.0 [M+H]+.PATENT

[0136]

[0137] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)- 2-(pyridin-2-ylamino)acetamide) (4f). Prepared from compound 3b (290 mg, 0.30 mmol) using Conditions A with a flash column gradient of 0-12% CH3OH / CH2C12. 4f was obtained as an orange oil (91 mg, 31% yield). 1H NMR (500 MHz, DMSO-d6): 67.86 (2H); 7.37 (2H); 6.58 (2H); 6.43 (4H); 5.30 (4H); 4.06 (4H); 3.39-3.11 (18H); 2.50-2.04 (10H); 1.97 (8H); 1.68 (2H); 1.54 (4H); 1.41 (2H); 1.38-1.04 (48H); 0.83 (6H). LC / MS: 94.1% purity, ES+ calc’d for C60H104N802968.83; found 970.0 [M+H]+.

[0138] 4g

[0139] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)- 5-(pyridin-2-ylamino)pentanamide) (4g). Prepared from compound 3f (313 mg, 0.30 mmol) using Conditions A. Two flash column steps were necessary to purify this compound to an acceptable level: 0-12% CH3OH / CH2C12, followed by 0-50% CH3OH / EtOAc. 4g was obtained as a yellow oil (132 mg, 42% yield). 1H NMR (500 MHz, DMSO-d6): 67.91 (2H); 7.26 (2H); 6.39 (6H); 5.30 (4H); 3.30 (2H); 3.23 (3H); 3.17 (10H); 2.41-2.10 (16H); 1.95PATENT(8H); 1.85 (2H); 1.63-1.32 (18H); 1.32-1.10 (47H); 0.82 (6H). LC / MS: 97.1% purity, ES+ calc’d for C66H116N8O2 1052.92; found 1054.2 [M+H]+.

[0140] 4h

[0141] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)-4-(pyridin-2-ylamino)butanamide) (4h). Prepared from compound 3e (400 mg, 0.39 mmol) using Conditions A with a flash column gradient of 0-40% CH3OH / EtOAc. 4h was obtained as a yellow solid (150 mg, 37% yield). 1H NMR (500 MHz, DMSO-d6): 67.92 (2H); 7.30 (2H); 6.39 (6H); 5.30 (4H); 3.18 (12H); 2.38-2.22 (11H); 2.17 (5H); 1.95 (8H); 1.89 (2H); 1.72 (4H); 1.56 (4H); 1.40 (5H); 1.33-1.12 (46H); 0.83 (6H). LC / MS: 98.2% purity, ES+ calc’d for 1024.89; found 1026.2 [M+H]+.

[0142]

[0143] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-(methyl(6- (trifluoromethyl)pyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)acetamide) (4i). Prepared from compound 3a (400 mg, 0.40 mmol) and 2-fluoro-6-trifluoromethylpyridine (3.34 g, 20.2 mmol) using Conditions B with a flash column gradient of 0-5% CH3OH / CH2C12. 4i was obtained as a yellow oil (263 mg, 57% yield). 1H NMR (500 MHz, DMSO-d6): 67.64 (2H);PATENT6.83 (2H); 6.94 (2H); 5.30 (4H); 4.40 (4H); 3.60 (4H); 3.17 (4H); 3.04 (6H); 2.99 (3H); 2.44- 2.04 (10H); 1.95 (8H); 1.72 (5H); 1.57 (4H); 1.37 (3H); 1.33-1.06 (47H); 0.82 (6H). LC / MS: 99.2% purity, ES+ calc’d for C64H106F6N8O2 1132.83; found 1033.9 [M+H]+.

[0144]

[0145] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)- 2-((5-(trifhioromethyl)pyridin-2-yl)amino)acetamide) (4j). Prepared from compound 3b (192 mg, 0.20 mmol) and 2-fhioro-5-trifhioromethylpyridine (1.65 g, 10.0 mmol) using Conditions B with a flash column gradient of 0-5% CH3OH / CH2C12. 4j was obtained as a yellow oil (132 mg, 60% yield). 1H NMR (500 MHz, DMSO-d6): 68.21 (2H); 7.60 (2H); 7.19 (2H); 6.75 (2H); 5.30 (4H); 4.18 (4H); 3.30 (8H); 3.02 (3H); 2.41-2.10 (13H); 1.96 (8H); 1.72 (5H); 1.59 (4H); 1.42 (3H); 1.39-1.02 (50H); 0.84 (6H). LC / MS: 99.0% purity, ES+ calc’d for C62H102F6N8O2 1104.80; found 1105.6 [M+H]+.

[0146]

[0147] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)- 4-((6-(trifluoromethyl)pyridin-2-yl)amino)butanamide) (4k). Prepared from compound 3e (210 mg, 0.20 mmol) and 2-fluoro-6-trifluoromethylpyridine (1.66 g, 10.0 mmol) using Conditions B. Two flash column steps were necessary to purify this compound to anPATENT acceptable level: 0-5% CH3OH / CH2C12, followed by 0-20% CH3OH / EtOAc. 4k was obtained as a yellow oil (120 mg, 50% yield). 1H NMR (500 MHz, DMSO-d6): 67.52 (2H); 7.08 (2H); 6.82 (2H); 6.67 (2H); 5.30 (4H); 3.18 (12H); 2.39-2.04 (16H); 1.95 (9H); 1.73 (5H); 1.55 (5H); 1.46-1.32 (7H); 1.31-1.01 (47H); 0.82 (6H). LC / MS: 99.8% purity, ES+ calc’d for C66H110F6N8O2 1160.87; found 1161.6 [M+H]+.

[0148]

[0149] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(N-((Z)-octadec-9-en-l-yl)- 2-((4-(trifluorornethyl)pyridin-2-yl)amino)acetamide) (41). Prepared from compound 3b (200 mg, 0.21 mmol) and 2-fluoro-4-trifluoromethylpyridine (859 mg, 5.20 mmol) using modified Conditions B. Fewer equivalents of the fluoropyridine component were used for this experiment only to reduce the extent of tri-arylated byproduct formation. The mixture was purified using a flash column gradient of 0-5% CH3OH / CH2C12. 41 was obtained as a yellow oil (95 mg, 41% yield). 1H NMR (500 MHz, DMSO-d6): 68.04 (2H); 7.04 (2H); 6.85 (2H); 6.62 (2H); 5.22 (4H); 4.08 (4H); 3.29 (5H); 2.82 (14H); 2.33-2.03 (9H); 1.94 (8H); 1.53 (16H); 1.45 (4H); 1.32 (3H); 1.27-0.88 (47H); 0.74 (6H). LC / MS: 94.5% purity, ES+ calc’d for C62H102F6N8O2 1104.80; found 1105.7 [M+H]+.

[0150] PATENT

[0151] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(4-((4-chloropyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)butanamide) (4m). Prepared from compound 3e (200 mg, 0.20 mmol) and 4-chloro-2-fluoropyridine (1.29 g, 9.8 mmol) using Conditions B with a flash column gradient of 0-10% CH3OH / CH2C12. 4m was obtained as a yellow oil (135 mg, 63% yield). 1H NMR (500 MHz, DMSO-d6): 67.88 (2H); 6.79 (2H); 6.47 (4H); 5.30 (4H); 3.19 (12H); 2.32 (8H); 2.16 (5H); 1.95 (8H); 1.71 (4H); 1.56 (4H); 1.40 (5H); 1.31-1.11 (46H); 0.82 (6H). LC / MS: 94.7% purity, ES+ calc’d for C64H110C12N8O2 1092.81; found 1093.8 [M+H]+.

[0152] 4n

[0153] N,N'-(piperazine-l,4-diylbis(propane-3,l-diyl))bis(2-((4-chloropyridin-2-yl)amino)-N-((Z)-octadec-9-en-l-yl)acetamide) (4n). Prepared from compound 3b (200 mg, 0.21 mmol) and 4-chloro-2-fluoropyridine (1.37 g, 10.4 mmol) using Conditions B with a flash column gradient of 0-10% CH3OH / CH2C12. 4n was obtained as a yellow oil (85 mg, 39% yield). 1H NMR (300 MHz, DMSO-d6): 67.89 (2H); 6.82 (2H); 6.70 (2H); 6.55 (2H); 5.30 (4H); 4.09 (4H); 2.41-2.12 (9H); 1.94 (8H); 1.82-1.41 (10H); 1.34-1.09 (47H); 0.82 (6H). LC / MS: 93.1% purity, ES+ calc’d for C60H102C12N802 1036.75; found 1037.7 [M+H]+.

[0154] PATENTTable 1. Summary of representative lipids synthesized. The “linker” description refers to the linkage between the heteroaryl group and the linear aliphatic chains. The “core” refers to either 2-dimethylaminopyridine (2-DMAP) or 2-aminopyridine (2-AmP).Table 2. Prepared Lipid Formulations. The formulations A-E in all of the charts and tables included each used the same wt:wt ratios of ePEELipid (ePEI = ethoxylated PEI).Example 3. Transfection efficiency for lipids without amino group in the linker to the heteroaryl group.

[0155] As shown in FIG. 4, formulations of lipids containing a 2-Aminopyridine ligand with an amino group on the pyridine ring and not part of the connecting linker often provided vg titers that exceeded those obtained with a pendant imidazole (e.g. TransIT reagent). The lipid with a primary amine and shortest linker (94) provided the highest titers. Switching to a dimethyl amine (92), extending the linker chain (96) or switching to a different lipid backbone (128) all still provided transfection, but titers were generally lessPATENT than those achieved using compound 94. In FIG. 4, All data was normalized relative to the TransIT results so that TransIT has a value of 1.0.Example 4. Transfection efficiency for lipids with the linker to the heteroaryl group attached via the amino group

[0156] FIG. 5 shows the average relative transfection efficiency results for formulations (A-E) of lipids containing a 2-Aminopyridine ligand with the linker chain attached via the amino group. As shown, while this configuration still provides useful levels of transfection, typically lower titers were observed relative to compounds where the amine on the pyridine was not part of the linker chain. This set of compounds also includes examples that have electron withdrawing groups on the pyridine rings (CF3 for 77, 89, 92.2; Cl for 65, 80, 95, 98) showing that the resulting lower pKas for those compounds appear to provide materials with lower overall performance than those with pKas closer to that of imidazole (e.g. 92, 94, 96, 128).Example 5. Transfection Assay of Representative Transfection Reagents

[0157] AAV Production: AAV8(GFP) was produced in a clonal cell line derived from HEK293F (Viral Production Cells 2.0, Gibco™) using a three-plasmid triple transfection system. Viral particles were produced by co-transfecting the three plasmids: pALD-HELP vector expressing Adeno E2A, Adeno E4 and Adeno VA helper factors (Aldevron™), pRep2Cap8-KanR vector expression Rep and Cap (Applied Viromics), and pALD-ITR-GFP vector expressing AAV inverted terminal repeats and GFP under control of a CMV promoter (Aldevron ™). Cells were seeded at 2.2x106 cells / mL in 4.75 or 4.50 mL of BalanCD HEK293 (Fujilrvine) supplemented with 4 mM GlutaMAX™ (Gibco™) in T-25 untreated culture flasks. Cells were incubated at 37°C in an 8% CO2 in air atmosphere under agitation (130 rpm) during DNA complexation.

[0158] The three DNA plasmids (10 pg total DNA per T-25 flask) were combined in a mass ratio of 1:1:1 (pALD-HELP:pRep2Cap8-KanR:pALD-ITR-GFP). The combined plasmids were diluted into a total volume of 0.25 mL or 0.5 mL Opti-MEM™ I (Gibco™). Then 10,15, or 20 pL of solutions containing the 2-AminoPyridine lipid compounds / cationic polymer (resulting in ratios of 1, 1.5, or 2 pL per pg of DNA) were added to the diluted DNA. The complexation solution was mixed via gentle trituration, and incubated 30, 25, or 15 min at rt. Transfection complexes were added to the cell cultures and the flasks werePATENT incubated for 72 hr at 37°C in an 8% CO2 in air atmosphere under agitation (130 rpm). Cell viability was determined at 72 hr by trypan blue dye exclusion assay.

[0159] dPCR Analysis for Viral Genomes per milliliter (VG / mL): Viral genomes (VG / mL) was determined by digital polymerase chain reaction (dPCR) assay. Exogenous DNA was digested with Denarase® at 50U / mL of harvest material for at least 90 minutes in the presence of 2mM magnesium chloride. Virus capsid was lysed by heating to 95°C for 10 minutes. The lysed capsid was then serially diluted through six 10-fold dilutions (final dilution factor 1,000,000-fold) and mixed with the PCR master mix consisting of QIAcuity Probe PCR Kit (Qiagen) and a custom primer probe set directed against the CMV promoter region of the packaged transgene. The PCR reaction mixture was then plated in a QIAcuity Nanoplate 8.5k 96- well (Qiagen) and dPCR was performed in a QIAcuity Digital PCR System (Qiagen). Data was analyzed by the QIAcuity Software Suite.

[0160] ELISA Analysis for Viral Particle per milliliter (VP / mL): Viral particles (VP / mL) was determined by ELISA assay using an AAV8 Xpress ELISA kit (Progen). The viral capsids were serially diluted through three 10-fold dilutions followed by three 3-fold dilutions (final dilution factor 8000-fold). The diluted virus was processed through the ELISA kit following the manufacturer instructions and the plate was read at a wavelength of 450 nm on a Cytation 5 Multimode Plate Reader (BioTek).

[0161] GFP: For GFP expression analysis, three days post transfection, a 500 pL sample of the cell culture supernatant was removed and 20 L propidium iodide (PI) was added for live / dead cell determination and the samples were incubated for 20 minutes at rt. GFP expression was analyzed (100,000 events) by flow cytometry (GFP Exc: 495 nm, Em filter: 530 / 30 nm, PI Exc 495 nm, Em filter: 695 / 40 nm) using an Attune NxT (Applied Biosciences). Compensation was applied to deconvolute the GFP and PI signals.

[0162] Transfection results of representative transfection compounds of this disclosure are shown in FIG. 3. The results demonstrate that the transfection reagents of this disclosure exhibit significant multi-fold transfection improvement over control transfection reagents.

[0163] All patents, publications, scientific articles, web sites, and other documents and materials referenced or mentioned herein are indicative of the levels of skill of those skilled in the art to which the invention pertains, and each such referenced document andPATENT material is hereby incorporated by reference to the same extent as if it had been incorporated by reference in its entirety individually or set forth herein in its entirety. Applicants reserve the right to physically incorporate into this specification any and all materials and information from any such patents, publications, scientific articles, web sites, electronically available information, and other referenced materials or documents. Reference to any applications, patents and publications in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

[0164] The specific methods and compositions described herein are representative of preferred embodiments and are exemplary and not intended as limitations on the scope of the invention. Other objects, aspects, and embodiments will occur to those skilled in the art upon consideration of this specification, and are encompassed within the spirit of the invention as defined by the scope of the claims. It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, or limitation or limitations, which is not specifically disclosed herein as essential. Thus, for example, in each instance herein, in embodiments or examples of the present invention, any of the terms “comprising”, “consisting essentially of’, and “consisting of’ may be replaced with either of the other two terms in the specification. Also, the terms “comprising”, “including”, containing”, etc. are to be read expansively and without limitation. The methods and processes illustratively described herein suitably may be practiced in differing orders of steps, and that they are not necessarily restricted to the orders of steps indicated herein or in the claims. It is also that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Under no circumstances may the patent be interpreted to be limited to the specific examples or embodiments or methods specifically disclosed herein. Under no circumstances may the patent be interpreted to be limited by any statement made by any Examiner or any other official or employee of the Patent and Trademark Office unless such statement is specifically and without qualification or reservation expressly adopted in a responsive writing by Applicants. Furthermore, titles, headings, or the like are provided to enhance the reader’s comprehension of this document, and should not be read as limiting the scope of the presentPATENT invention. Any examples of aspects, embodiments or components of the invention referred to herein are to be considered non-limiting.

[0165] The terms and expressions that have been employed are used as terms of description and not of limitation, and there is no intent in the use of such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention as claimed. Thus, it will be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0166] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[0167] Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

Claims

AMENDED CLAIMSreceived by the International Bureau on 11 September 2026 (11.09.2026)CLAIMS:What is claimed is:

1. Acompound of formula (I), (II), (III), or (IV):wherein n and m are independently selected from an integer from 1 to 18, b is an integer selected from 0 to 3,d is an integer selected from 0 to 3,g is an integer selected from 0 to 5,h is an integer selected from 0 to 5,Ri and R2are independently selected from a C8-C24saturated or unsaturated alkyl,Rx, Ry, R3 , R4, Rs and R6are independently selected from H, Ci_6unsubstituted alkyl, Ci_6substituted alkyl, or C2.6alkyl amide, or wherein R3and R4together form a C5-3cyclic alkyl or heterocyclyl, or wherein R5and R6together form a C5-s cyclic alkyl or heterocyclyl;J is selected from halogen, cyano, nitro, guanidino, amidino, hydroxy, CF3, -NR7R3, Ci_6unsubstituted alkyl, Ci_6substituted alkyl, -OR9, and sulfate, wherein R7and Rsare independently selected from Ci_6unsubstituted alkyl or Ci_6substituted alkyl or hydrogen, wherein R9is selected from Ci_6unsubstituted alkyl or Ci_6substituted alkyl,R10 and Rn are independently selected from H, Ci_6unsubstituted alkyl, Ci_6substituted alkyl, C2-6alkyl amide, heteroaryl, aryl, or R10 and Rn together form a 5- to 8-membered heterocyclyl,or a salt thereof.

2. The compound of claim 1 , wherein the compound has a structure of formula (V):

3. The compound of claim 1 , wherein the compound has a structure of formula (I- a):wherein e is an integer selected from 0 to 3.

4. The compound of claim 1 , wherein the compound has a structure of formula (I- aa):

5. The compound of claim 1 , wherein Ri and R2are independently selected from a C10-C24 unsaturated alkyl.

6. The compound of claim 1 , wherein the compound has a structure of formula (VI), formula (VII), or formula (VIII), orformula (IX), orformula (XII):

7. The compound of claim 1 , wherein the compound has a structure of formula (X) or (XI):wherein Ri and R2are independently selected from a Ci0-C24saturated or unsaturated alkyl,R3, R4, Rs and R6are independently selected from H, Ci_6unsubstituted alkyl, Ci_6substituted alkyl, or C2.6alkyl amide,ora salt thereof.

8. The compound of claim 1 , wherein R3, R4, Rs and R6are each H.

9. The compound of claim 1 , wherein the compound has a pKa in the range of 5.5 to 8.0.

10. The compound of claim 9, wherein the compound has a pKa in the range of 6.4 to 6.6.

11. A transfection composition comprisinga compound of claim 1, and a cationic polymer.

12. The transfection composition of claim 11 , further comprising a nucleic acid.

13. The transfection composition of claim 12, wherein the nucleic acid is selected from DNA, shRNA, siRNA, circRNA, or mRNA.

14. The transfection composition of claim 13, wherein the DNA is plasmid DNA.

15. The transfection composition of claim 13, wherein the mRNA comprises pseudouridine, a 5-methylcytidine residue, a 5'-cap, a 5'-cap 1 structure, a 3'- poly(A) tail, or combinations thereof.

16. The transfection composition of claim 11 , wherein the cationic polymer is selected from: polyethyleneimine, ethoxylated polyethyleneimine, polypropyleneimine, poly(amidoamine), polyamine dendrimers from Goto G4(PAMAM), polyhydroxyalkylamine, poly(butyleneimine), spermine, polyallylamine, and N-substituted polyallylamine wherein the substitution on N is Ci-6alkyl or hydroxy.

17. The transfection composition of claim 16, wherein the cationic polymer is polyethyleneimine.

18. A method for transfecting a cell, the method comprising contacting the cell with a transfection composition of claim 11.